Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 21, 2001, Pages 48-52

  Dinan, T G ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PLACEBO;

ADULT; AGED; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG COATING; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MULTICENTER STUDY; NERVOUSNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SUICIDAL BEHAVIOR;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDERS; COMORBIDITY; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME;

EID: 0034791597     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Practice guideline for major depressive disorder in adults
2. Pharmacotherapy of depressive disorders. WHO consensus statement
3. Selective serotonin reuptake inhibitor treatment in the UK: Risk of relapse or recurrence of depression
4. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression
5. Selective contracting and patient outcomes: A case study of formulary restrictions for selective serotonin reuptake inhibitor antidepressants
6. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks
7. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication
8. Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients
9. Depot antipsychotics in bipolar affective disorder
10. Plasma-level response relationships with fluoxetine and zimelidine
11. Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing
12. Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: Results of a placebo-controlled, randomized clinical trial
13. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder
14. Anxiety syndromes and their relationship to depressive illness
15. Long-term treatment outcomes of depression/anxiety
16. Optimal length of a continuation therapy in depression: A prospective assessment during long-term fluoxetine treatment
17. Long-term outcomes of highly anxious depressed patients: Evidence from a 52-week randomized, controlled trial with fluoxetine